-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DG0jaqvo7AKYXLXe3seaAV6N93eRwAeIAwZrMyFk4SoN8VAAubOBC9DMajwfwg4Z 1UoQmjCaDwFTClpX2UvSXw== 0000893220-97-000365.txt : 19970222 0000893220-97-000365.hdr.sgml : 19970222 ACCESSION NUMBER: 0000893220-97-000365 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970214 SROS: NONE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: COLLAGENEX PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001012270 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 521758016 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-47825 FILM NUMBER: 97534855 BUSINESS ADDRESS: STREET 1: 301 SOUTH STATE ST CITY: NEWTON STATE: PA ZIP: 18940 BUSINESS PHONE: 2155797388 MAIL ADDRESS: STREET 1: 301 SOUTH STATE ST CITY: NEWTON STATE: PA ZIP: 18940 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: FAIRFAX PARTNERS THE VENTURE FUND OF WASHINGTON L P CENTRAL INDEX KEY: 0001033341 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 8000 TOWERS CRESCENT DRIVE SUITE 940 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7038479486 SC 13G 1 SCHEDULE 13G COLLAGENEX PHARMACEUTICALS, INC 1 ------------------------------- OMB APPROVAL ------------------------------- OMB Number: 3235-0145 Expires: December 31, 1997 Estimated average burden hours per response....14.90 ------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ____)* COLLAGENEX PHARMACEUTICALS, INC. ----------------------------------------- (Name of Issuer) COMMON STOCK ----------------------------------------- (Title of Class of Securities) 03746E102 ----------------------------------------- (CUSIP Number) Check the following box if a fee is being paid with this statement [ ]. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 8 pages 2 CUSIP NO. _________ 13G Page 2 of 4 Pages 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS FAIRFAX PARTNERS/THE VENTURE FUND OF WASHINGTON I.R.S. Identification No. 54-1508777 --------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] INAPPLICABLE --------------------------------------------------------------------- 3 SEC USE ONLY --------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION DELAWARE --------------------------------------------------------------------- 5 SOLE VOTING POWER NUMBER OF 446,517 SHARES -------------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER OWNED BY 0 EACH -------------------------------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON WITH 446,517 -------------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 -------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 446,517 --------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] INAPPLICABLE --------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.9% --------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* PN --------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! Page 2 of 8 pages 3 PAGE 3 OF 4 ITEM 1 (a) The name of the Issuer is CollaGenex Pharmaceuticals, Inc. (b) The address of the Issuer's Principal Executive Offices is: 301 South State Street, Newtown, PA. 18940. ITEM 2 (a) The filer is a limited partnership, named Fairfax Partners/The Venture Fund of Washington, L.P. (the "Partnership"). (b) The address of the filer's Principal Business Office is: 8000 Towers Crescent Drive, Suite 940, Vienna, VA. 22182 (c) U.S.A. (d) Common Stock (e) The Issuer's CUSIP number is: 19419B ITEM 3 Item 3 relating to statement filed pursuant to Rule 13d-1(b) or 13d-2(b) is inapplicable. ITEM 4 (a) The amount of shares beneficially owned is 446,517 (b) The percent of the Class is 5.9% (c) The Partnership has the sole power to vote, and the sole power to dispose of, all shares set forth in this Item 4(a). (d) The Partnership has the right to acquire 25,000 additional shares of stock under an option agreement which is held by Stephen W. Ritterbush for the benefit of the Partnership. 4 PAGE 4 OF 4 ITEM 5 This Item 5 is inapplicable. ITEM 6 This Item 6 is inapplicable. ITEM 7 This Item 7 is inapplicable. ITEM 8 This Item 8 is inapplicable. ITEM 9 This Item 9 is inapplicable. ITEM 10 This Item 10 is inapplicable. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 14, 1997 Fairfax Partners/The Venture Fund of Washington, L.P. By: American Venture Partners, L.P., its General Partner By: /s/ STEPHEN W. RITTERBUSH --------------------------------------- Stephen W. Ritterbush, its Managing General Partner -----END PRIVACY-ENHANCED MESSAGE-----